Hefter Harald, Kruschel Theodor S, Novak Max, Rosenthal Dietmar, Luedde Tom, Meuth Sven G, Albrecht Philipp, Hartmann Christian J, Samadzadeh Sara
Departments of Neurology, University of Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany.
Departments of Gastroenterology, University of Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany.
J Clin Med. 2023 Jul 24;12(14):4861. doi: 10.3390/jcm12144861.
The aim of this study was to demonstrate that both neurological and hepatic symptoms respond to copper chelation therapy in Wilson disease (WD). However, the time course of their recovery is different.
Eighteen patients with neurological WD from a single specialized center who had been listed for liver transplantation during the last ten years and two newly diagnosed homozygous twins were recruited for this retrospective study. The mean duration of conventional treatment was 7.3 years (range: 0.25 to 36.2 years). A custom Wilson disease score with seven motor items, three non-motor items, and 33 biochemical parameters of the blood and urine, as well as the MELD score, was determined at various checkup visits during treatment. These data were extracted from the charts of the patients.
Treatment was initiated with severity-dependent doses (≥900 mg) of D-penicillamine (DPA) or triethylene-tetramin-dihydrochloride (TRIEN). The motor score improved in 10 and remained constant in 8 patients. Worsening of neurological symptoms was observed only in two patients who developed comorbidities (myasthenia gravis or hemispheric stroke). The neurological symptoms continuously improved over the years until the majority of patients became only mildly affected. In contrast to this slow recovery of the neurological symptoms, the MELD score and liver enzymes had already started to improve after 1 month and rapidly improved over the next 6 months in 19 patients. The cholinesterase levels continued to increase significantly ( < 0.0074) even further. One patient whose MELD score indicated further progression of liver disease received an orthotopic liver transplantation 3 months after the diagnosis of WD and the onset of DPA treatment.
Neurological and hepatic symptoms both respond to copper chelation therapy. For patients with acute liver failure, the first 4 months are critical. This is the time span in which patients have to wait either for a donor organ or until significant improvement has occurred under conventional therapy. For patients with severe neurological symptoms, it is important that they are treated with fairly high doses over several years.
本研究的目的是证明威尔逊病(WD)患者的神经症状和肝脏症状对铜螯合疗法均有反应。然而,它们恢复的时间进程有所不同。
本回顾性研究招募了来自单一专科中心的18例过去十年中被列入肝移植名单的神经型WD患者以及2例新诊断的纯合子双胞胎。常规治疗的平均时长为7.3年(范围:0.25至36.2年)。在治疗期间的不同检查访视中,确定了一个定制的威尔逊病评分,包括7项运动项目、3项非运动项目以及血液和尿液的33项生化参数,还有终末期肝病模型(MELD)评分。这些数据从患者病历中提取。
治疗起始采用依严重程度而定的剂量(≥900 mg)的青霉胺(DPA)或三乙烯四胺二盐酸盐(TRIEN)。10例患者的运动评分改善,8例保持不变。仅在2例出现合并症(重症肌无力或半球性卒中)的患者中观察到神经症状恶化。多年来神经症状持续改善,直至大多数患者仅受到轻度影响。与神经症状的这种缓慢恢复形成对比的是,19例患者的MELD评分和肝酶在1个月后已开始改善,并在接下来的6个月内迅速改善。胆碱酯酶水平甚至进一步持续显著升高(<0.0074)。1例MELD评分表明肝病进一步进展的患者在诊断WD并开始DPA治疗3个月后接受了原位肝移植。
神经症状和肝脏症状对铜螯合疗法均有反应。对于急性肝衰竭患者,前4个月至关重要。在此时间段内,患者必须等待供体器官或等待在常规治疗下出现显著改善。对于有严重神经症状的患者,重要的是在数年中用相当高的剂量进行治疗。